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Abstract
Introduction: We sought to examine the cardiac consequences of early administration of norepinephrine in
severely hypotensive sepsis patients hospitalized in a medical intensive care unit of a university hospital.
Methods: We included 105 septic-shock patients who already had received volume resuscitation. All received
norepinephrine early because of life-threatening hypotension and the need to achieve a sufficient perfusion
pressure rapidly and to maintain adequate flow. We analyzed the changes in transpulmonary thermodilution
variables associated with the increase in mean arterial pressure (MAP) induced by norepinephrine when the
achieved MAP was ≥65 mm Hg.
Results: Norepinephrine significantly increased MAP from 54 ± 8 to 76 ± 9 mm Hg, cardiac index (CI) from 3.2 ±
1.0 to 3.6 ± 1.1 L/min/m
2, stroke volume index (SVI) from 34 ± 12 to 39 ± 13 ml/m
2, global end-diastolic volume
index (GEDVI) from 694 ± 148 to 742 ± 168 ml/m
2, and cardiac function index (CFI) from 4.7 ± 1.5 to 5.0 ± 1.6 per
min. Beneficial hemodynamic effects on CI, SVI, GEDVI, and CFI were observed in the group of 71 patients with a
baseline echocardiographic left ventricular ejection fraction (LVEF) >45%, as well as in the group of 34 patients
with a baseline LVEF ≤45%. No change in CI, SVI, GEDVI, or CFI was observed in the 17 patients with baseline LVEF
≤45% for whom values of MAP ≥75 mm Hg were achieved with norepinephrine.
Conclusions: Early administration of norepinephrine aimed at rapidly achieving a sufficient perfusion pressure in
severely hypotensive septic-shock patients is able to increase cardiac output through an increase in cardiac preload
and cardiac contractility. This effect remained in patients with poor cardiac contractility except when values of MAP
≥75 mm Hg were achieved.
Introduction
International recommendations have placed either nore-
pinephrine or dopamine as a first-line vasopressor during
septic shock [1]. Norepinephrine is considered more
potent [1,2] and induces fewer adverse effects than dopa-
mine [3]. However, the effects of norepinephrine on car-
diac output and heart function of sepsis patients are
uncertain. Norepinephrine can increase cardiac output
through several mechanisms: (a) improvement of the left
ventricular function explained by two effects: direct
b1-agonist inotropic effect and a-agonist-mediated
restoration of diastolic arterial pressure that represents
the driving pressure for coronary perfusion of the left
heart; (b) increase in cardiac preload secondary to the
a-agonist-mediated decrease in systemic venous capaci-
tance [4]. Conversely, norepinephrine could decrease car-
diac output owing to an increase in left ventricular
afterload. This latter effect is assumed to be significant if
the left ventricular function is already impaired or if an
excessive mean arterial pressure (MAP) is targeted, or
both. Variable results were reported in studies examining
the effects of norepinephrine on cardiac output in septic-
shock patients [2,5-12]. This variability can be ascribed to
differences in the underlying cardiac function, or the
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preload optimization or a combination of these. In most
previous studies [2,5,9,11], the cardiac output was not
altered by norepinephrine, but the drug was administered
under conditions of a hyperdynamic state, generally after
abundant fluid administration. Because of the recent
emphasis on urgent and aggressive resuscitation as a key
issue in the management of septic shock [13], current
international guidelines recommend to administer a
vasopressor early to sustain life and maintain perfusion
in the face of life-threatening hypotension, even when
hypovolemia has not yet been resolved [1]. We hypothe-
sized that under such conditions, norepinephrine is cap-
able of increasing cardiac output through an increase in
cardiac preload. We aimed at checking this hypothesis in
an observational study performed in a series of septic-
shock patients who early received norepinephrine to
maintain perfusion in the face of life-threatening hypo-
tension [1]. We paid particular attention to patients with
prior left ventricular dysfunction and particularly when a
high MAP value was achieved.
Materials and methods
Patients
This was an observational study undertaken over a per-
iod of 16 months in patients admitted into the medical
intensive care unit (ICU) of the Bicêtre University Hos-
pital for septic shock, as defined by the Surviving Sepsis
Campaign [1]. The study was approved by the Institu-
tional Review Board of our institution (Comité pour la
protection des personnes de l’Hôpital de Bicêtre), and
all patients or their relatives gave their informed consent
for the patient’s data to be used in the analysis.
The patient’s data were included in the analysis (a) if the
patients were admitted into the ICU for less than 6 hours,
and (b) when the MAP was lower than 65 mm Hg and the
attending physician considered it necessary to introduce
norepinephrine or increase its dose with the goal of
increasing the MAP to above 65 mm Hg. In line with the
current recommendations [1], our physicians are used to
introducing norepinephrine (or increasing its dose) early
in the case of life-threatening hypotension, regardless the
degree of prior volume resuscitation and in particular if
the diastolic blood pressure remains low (≤40 mm Hg or
more in case of prior hypertension) [14]. Another criterion
of inclusion was that a PiCCOplus monitor (Pulsion Medi-
cal Systems, Munich, Germany) was already in place for
routine hemodynamic monitoring.
The criteria of exclusion were the need for simulta-
neously administering other vasoactive drugs or a new
fluid challenge or blood transfusion and the need for
modifying the ventilatory settings or the dose of the
sedative drugs.
Hemodynamic variables
The PiCCOplus device allowed continuous measuring of
the arterial pressure and the heart rate through a
femoral arterial catheter. Each time the attending physi-
cian decided to perform any therapeutic intervention
such as introduction of norepinephrine or increase in its
doses, a series of three 15-ml saline solution boluses
were performed through the central venous access
before and after the intervention. The average of the
three values of transpulmonary thermodilution cardiac
index (CI) was then recorded. Other transpulmonary
thermodilution variables were recorded: the stroke
volume index (SVI) calculated as CI/heart rate, the glo-
bal end-diastolic volume index (GEDVI) assumed to be
a global cardiac preload indicator [15,16], and the car-
diac function index (CFI), considered an indicator of the
systolic cardiac function [17-19]. An index of systemic
vascular resistance (SVRI) w a sc a l c u l a t e da sM A P / C I .
The stroke-volume variation (SVV) automatically calcu-
lated by the PiCCOplus monitor, was collected in the
mechanically ventilated patients who were fully adapted
to their ventilator and who did not exhibit cardiac
arrhythmias.
Because we are used to performing transthoracic
echocardiography (EnVisor Philips B.0; Philips Medical
System, Andover, MA) in patients with shock as soon as
possible after their admission, we were able to collect
baseline measurements of the left ventricular ejection
fraction (LVEF) by using the Simpson’sm e t h o df r o m
the apical two- and four-chamber views.
Data analysis
We analyzed the hemodynamic variables recorded at
two consecutive time points: before and after either
introduction of norepinephrine or increase in its dose,
while the achieved value of MAP was ≥65 mm Hg. The
time between the two consecutive measurements did
not exceed 2 hours.
We subdivided our population into two groups in
function of the median value of MAP achieved with
norepinephrine at the second time point. We then sepa-
rately analyzed the hemodynamic variables depending
on whether the median value of MAP was reached.
We also subdivided the whole population into two
groups in function of the existence of altered LVEF at
b a s e l i n e ,d e f i n e db yat h r e s h o l dv a l u eo f4 5 % .W et h e n
examined the hemodynamic consequences of norepi-
nephrine in patients with LVEF >45% and in patients
with LVEF ≤45%. In these two subgroups, we also calcu-
lated the median value of MAP reached with norepi-
nephrine at the second time point and then separately
analyzed the hemodynamic variables depending on
whether the median value of MAP was reached.
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All data were normally distributed (Kolmogorov-Smir-
nov test for normality), except the dose of norepinephr-
ine. The results are expressed as the mean ± SD or as
the median (25th to 75th percentile), as appropriate.
The statistical comparisons were made by using the
paired Student t test or the Wilcoxon test, as appropri-
ate. A P value of 0.05 was considered statistically signifi-
cant. All the statistical comparisons were carried out by
using Medcalc 9.3.1.0 (Mariakerke, Belgium).
Results
We included 105 patients within the first 6 hours of
their admission in the ICU. Their general characteristics
are presented in Table 1. At baseline, the diastolic arter-
ial pressure was ≤40 mm Hg in 67 patients, between 41
and 48 mm Hg in 30 patients (70% of them had a his-
tory of hypertension), and between 49 and 55 mm Hg
in eight patients (all of them had a history of
hypertension).
The median volume of saline infused in our ICU
before inclusion in the study was of 1,000 [500 to 1,500]
ml. The median interval between two time points was
60 (30 to 90) minutes.
Before inclusion, 57 patients were already receiving
norepinephrine at a dose ineffective to achieve a MAP
>65 mm Hg (or >75 mm Hg in cases of prior hyperten-
sion). In these patients, the dose of norepinephrine was
increased from 0.40 (0.24 to 0.59) μg/kg/min to 0.60
(0.47 to 0.95) μg/kg/min (P < 0.001). In the remaining
48 patients, norepinephrine was introduced at the time
of the study. Its dose reached a median value of 0.24
(0.18 to 0.47) μg/kg/min at the second time point.
Patients did not receive other drugs, except antibiotics
(for all of them) and sedative drugs for those receiving
mechanical ventilation (propofol alone or in combina-
tion with fentanyl or remifentanyl).
Effects of norepinephrine in the whole population
Norepinephrine significantly increased CI, SVI, GEDVI,
and CFI in the global population (Table 2). The signifi-
cant increases in CI, SVI, GEDVI, and CFI were found
in the subgroup of 48 patients in whom norepinephrine
was introduced, as well as in the subgroup of 57 patients
in whom the dose of norepinephrine was increased (data
not presented). Figures 1 and 2 present the percentage
changes in CI and MAP before and after norepinephrine
introduction/increase in these two subgroups.
In the 59 mechanically ventilated patients (tidal
volume, 6.7 ± 1.0 ml/kg) in whom the SVV was
recorded, norepinephrine introduction/increase signifi-
cantly decreased the SVV from 13 ± 6% to 9 ± 5%. In
this subgroup, introduction/increase of norepinephrine
also significantly increased CI, SVI, GEDVI, and CFI
(data not presented).
The median MAP value achieved after norepinephrine
introduction/increase was 75 mm Hg. The achieved
MAP was >85 mm Hg in 16% of patients. The increasing
effects of norepinephrine on CI, SVI, GEDVI, and CFI
were found in the subgroup of 53 patients with an
achieved value of MAP <75 mm Hg, as well as in the sub-
group of 52 patients with an achieved value of MAP of
≥75 mm Hg (Table 3). Figures 3 and 4 present the indivi-
dual changes in SVI and GEDVI in the two subgroups.
Effects of norepinephrine in patients with a baseline LVEF
>45%
Seventy-one patients had a baseline LVEF >45% (median
LVEF, 55(50 to 60)%). In this population, norepinephrine
Table 1 General patients’ characteristics
Values
Number of patients 105
Age, years 63 ± 12
Sex ratio, male/female 71/34
Mechanically ventilated patients, % 86
Baseline plasma lactate concentration, mmol/L 3.8 ± 1.2
SOFA 12 ± 2
SAPS II 57 ± 12
Prior hypertension, n 29
Prior cardiomyopathy, n 30
Baseline left ventricular ejection fraction, % 49 ± 10
Origin of sepsis
Lung, n 83
Abdomen, n 10
Urinary tract, n 8
Others, n 4
Table 2 Hemodynamic variables before and after
introduction of norepinephrine (or increase in its dose)
in the whole population (n = 105)
Before
norepinephrine
(introduction/
increase)
After norepinephrine
(introduction/
increase)
Heart rate, beats/min 98 ± 21 97 ± 19
MAP, mm Hg 54 ± 8 76 ± 9
a
DAP, mm Hg 38 ± 6 52 ± 8
a
CI, L/min/m
2 3.2 ± 1.0 3.6 ± 1.1
a
SVI, ml/m
2 34 ± 12 39 ± 13
a
GEDVI, ml/m
2 694 ± 148 742 ± 168
a
CFI, per minute 4.7 ± 1.5 5.0 ± 1.6
a
SVRI, dynes/sec/cm
5/
m
2
1,471 ± 481 1,822 ± 502
a
CFI, cardiac function index; CI, cardiac index; DAP, diastolic arterial pressure;
GEDVI, global end-diastolic volume index; HR, heart rate; MAP, mean arterial
pressure; SVI, stroke volume index; SVRI, index of systemic vascular resistance.
aP < 0.05 vs. before norepinephrine.
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Figure 5 presents the individual changes in SVI and
GEDVI in this subgroup.
When subdividing this group of patients by the func-
tion of their median value (75 mm Hg), these effects
were found in the subgroup of 36 patients with an
achieved MAP <75 mm Hg, as well as in the subgroup
of 35 patients with an achieved value ≥75 mm Hg
(Table 5).
Effects of norepinephrine in patients with a baseline
LVEF ≤45%
Thirty-four patients had a baseline LVEF ≤45% (mean
LVEF, 40(35 to 40)%). In this population, norepinephrine
significantly increased CI, SVI, and GEDVI (Table 4).
Figure 6 presents the individual changes in SVI and
GEDVI in this subgroup.
When subdividing this group of patients in function of
their median value (75 mm Hg), these effects were
found in the subgroup of 17 patients with an achieved
M A P< 7 5m mH g .H o w e v e r ,C I ,S V I ,a n dG E D V Id i d
not change in the subgroup of 17 patients with an
achieved value ≥75 mm Hg (Table 6).
Discussion
The main result of this study performed during life-
threatening septic shock is that early administration of
norepinephrine aimed at restoring a sufficient MAP was
associated with increases in CI and SVI, which were
likely related to increases in both cardiac preload and
contractility. In patients with cardiac systolic dysfunc-
tion, norepinephrine exerted either beneficial or neutral
but not deleterious hemodynamic effects.
One of the striking effects of norepinephrine in our
patients was its cardiac preload effect. In our whole
population, norepinephrine significantly increased CI,
SVI, and GEDVI, which is considered a measure of car-
diac preload [15,16]. Moreover, norepinephrine signifi-
cantly reduced SVV, which is a marker of volume
responsiveness [20]. This result was in line with the
reduction in pulse-pressure variation with norepinephr-
ine reported by Sennoun et al. [21] in animals after endo-
toxin administration. Such fin d i n g sc o u l db ea s c r i b e dt o
the a-mediated effect of reduction in systemic venous
capacitance [4]. This hypothesis is in agreement with a
previous clinical study that reported an elevation of the
central blood volume–measured by transpulmonary ther-
modilution–in response to an acute norepinephrine-
induced increase in systemic vascular resistance [22]. In
our study, two findings suggest that many of our patients
still had some preload reserve before norepinephrine
introduction/increase: (a) the fact that GEDVI and CI
both increased, and (b) the fact that the mean baseline
SVV was above the presumed threshold value detecting
volume responsiveness [20], and this in despite a rather
low tidal volume. This was quite expected because nore-
pinephrine infusion was started early, on the basis of a
life-threatening hypotension, defined by a low diastolic
arterial pressure ≤40 mm Hg and not after that volume
resuscitation had been completed, as recommended by
the French consensus conference [14]. Because we
included many patients with prior hypertension, we
sometimes introduced norepinephrine (or increased its
dose) while the diastolic arterial pressure was between 40
and 55 mm Hg. The dose of norepinephrine was left to
the discretion of our attending physicians, who are used
to targeting an MAP value ≥65 mm Hg in patients
with no history of hypertension and generally more than
Figure 1 Relative percentage changes in the cardiac index (CI)
and the mean arterial pressure (MAP) before and after
introduction of norepinephrine in the subgroup of 48 patients
with no norepinephrine at baseline. The arrows indicate the
directions of these changes.
Figure 2 Relative percentage changes in the cardiac index (CI)
and the mean arterial pressure (MAP) before and after
increase in the dose of norepinephrine in the subgroup of 57
patients who already received norepinephrine at baseline. The
arrows indicate the directions of these changes.
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hypertension. This clinical practice was quite in agree-
ment with current recommendations [1,14]. The findings
of this observational study show that these goals were
fairly well achieved. The achieved value of MAP was
<75 mm Hg in one half of the population and ≥75 mm
Hg and in the other half. It must be stressed that only
16% of patients had an achieved MAP ≥85 mm Hg, a
value that is generally considered the average MAP of the
normal population [23].
In our whole population, norepinephrine also
increased CFI, which is considered a global index of car-
diac systolic function [17-19] and thus is assumed to
depend on both contractility and afterload. In the face
of the increase in MAP and hence in left ventricular
afterload, the increase in CFI induced by norepinephrine
suggests that this drug actually increased the cardiac
contractility. By using fast-response thermodilution,
Martin et al. [24] reported an improved right ventricular
function in septic-shock patients treated with norepi-
nephrine and attributed this beneficial effect to the
b1-agonist effect of the drug or to its ability to increase
the coronary perfusion pressure by correcting systemic
hypotension or both. These two mechanisms were likely
to have occurred in our patients. First, it is expectable
that the sepsis-induced decreased responsiveness of the
myocardium to b-adrenergic stimulation [25] was not
yet complete in our patients, because they were studied
at a very early stage of their disease. Second, because
our patients either did not receive catecholamine before
inclusion or received norepinephrine only a short time
before inclusion, it is unlikely that downregulation of
Table 3 Hemodynamic variables in the whole population depending on whether the achieved mean arterial pressure
after introduction of norepinephrine (or increase in its dose) was either inferior (n = 53) or superior (n = 52) to the
median value (75 mm Hg)
Achieved MAP <75 mm Hg Achieved MAP ≥75 mm Hg
Before NE
(introduction/increase)
After NE
(introduction/increase)
Before NE
(introduction/increase)
After NE
(introduction/increase)
Heart rate, beats/min 103 ± 20 101 ± 20 93 ± 21 94 ± 20
MAP, mm Hg 51 ± 7 68 ± 4
a 57 ± 7 83 ± 6
a
DAP, mm Hg 36 ± 7 48 ± 7
a 40 ± 6 56 ± 8
a
CI, L/min/m
2 3.2 ± 1.1 3.6 ± 1.1
a 3.2 ± 0.9 3.7 ± 1.1
a
SVI, ml/m
2 32 ± 12 37 ± 13
a 38 ± 12 42 ± 14
a
GEDVI, ml/m
2 698 ± 139 752 ± 161
a 691 ± 157 743 ± 181
a
CFI, per min 4.7 ± 1.8 4.9 ± 1.7
a 4.8 ± 1.3 5.1 ± 1.5
a
SVRI, dynes/sec/cm
5/m
2 1,435 ± 535 1,704 ± 592
a 1,497 ± 542 1,937 ± 582
a
CFI, cardiac function index; CI, cardiac index; DAP, diastolic arterial pressure; GEDVI, global end-diastolic volume index; HR, heart rate; MAP, mean arterial
pressure; NE, norepinephrine; SVI, stroke volume index; SVRI, index of systemic vascular resistance.
aP < 0.05 vs. before norepinephrine.
Figure 3 Relative changes in the individual values of the stroke
volume index (SVI) and of the end-diastolic volume index
(GEDVI) before and after norepinephrine introduction (or
increase in its doses) in the subgroup of 53 patients with an
achieved value MAP value <75 mm Hg. The arrows indicate the
directions of these changes.
Figure 4 Relative changes in the individual values of the stroke
volume index (SVI) and of the end-diastolic volume index
(GEDVI) before and after norepinephrine introduction (or
increase in its doses) in the subgroup of 52 patients with an
achieved MAP value of ≥75 mm Hg. The arrows indicate the
directions of these changes.
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laxis mechanism [26]. In two recent studies performed
in patients with septic shock who received norepinephr-
ine after optimization of preload, norepinephrine
increased CI and SVI while the achieved MAP value
was ≥85 mm Hg [27,28]. Their results suggest that nore-
pinephrine could have exerted a positive inotropic effect.
In our study, we globally found the same results in the
group of 71 patients with a baseline LVEF >45% than in
the whole population. Even in the group of 34 patients
with a baseline LVEF ≤45%, norepinephrine increased
SVI and CI. These results must be underlined because
an increase in left ventricular afterload has the potential
to reduce SVI in cases of impaired cardiac contractility.
It is likely that the preload effect of norepinephrine was
important in these patients, who probably still had some
cardiac preload reserve. However, in the subset of
17 patients with both a baseline LVEF ≤45% and an
achieved MAP ≥75 mm Hg, norepinephrine introduc-
tion/increase did not change SVI and CI. It is possible
that in these patients, a “negative” afterload effect coun-
terbalanced the beneficial effects of this agent. Whether
targeting a lower MAP would have resulted in an
increased SVI in this particular category of patients was
not tested in our study.
Our study has some limitations. Because of the observa-
tional nature of the study, we were able to analyze only
time points when the achieved MAP value was ≥65 mm
Hg. We could not thus ascertain that norepinephrine
exerts positive hemodynamic effects when a MAP
<65 mm Hg is reached. Half of our patients had an
achieved MAP ≥75 mm Hg, a value that can be judged
relatively high, although it was still far lower than the aver-
age MAP of the normal population (>85 mm Hg) [23].
However, our studied population included many old
patients or patients with preexisting comorbidities and
particularly preexisting hypertension, or both. Under these
conditions, the international guidelines currently recom-
mend to target MAP at a higher level than that in patients
without comorbidities [1]. In addition, it must be remem-
bered that in the study by Rivers et al. [13], the MAP actu-
ally reached an average value of 95 mm Hg after 6 hours
of hemodynamic treatment in the protocol group, whereas
it was initially planned to target the MAP between 65 and
90 mm Hg. We used an LVEF value of 45% as a threshold
to define cardiac systolic dysfunction, as did other investi-
gators [29]. In the presence of low MAP and hence of low
afterload, an LVEF ≤45% is presumed to be indicative of a
poor left ventricular contractility. We evaluated the short-
term effect of norepinephrine on hemodynamics and thus
cannot exclude different effects of norepinephrine after a
longer period. We studied septic-shock patients with life-
threatening hypotension requiring early administration of
norepinephrine, regardlesst h ed e g r e eo fp r i o rv o l u m e
Table 4 Hemodynamic variables depending on whether the baseline value of the left ventricular function was either
≤45% (n = 34) or >45% (n = 71)
LVEF ≤45% LVEF >45%
Before NE
(introduction/increase)
After NE
(introduction/increase)
Before NE
(introduction/increase)
After NE
(introduction/increase)
Heart rate, beats/min 96 ± 17 94 ± 17 93 ± 21 94 ± 20
MAP, mm Hg 54 ± 9 75 ± 9
a 54 ± 7 76 ± 9
a
DAP, mm Hg 38 ± 7 52 ± 9
a 38 ± 6 52 ± 8
a
CI, L/min/m
2 2.9 ± 0.9 3.3 ± 0.9
a 3.2 ± 0.9 3.7 ± 1.1
a
SVI, ml/m
2 32 ± 11 35 ± 12
a 36 ± 13 41 ± 15
a
GEDVI, ml/m
2 719 ± 161 768 ± 190
a 683 ± 140 731 ± 157
a
CFI, per min 4.2 ± 1.4 4.4 ± 1.5 5.0 ± 1.6 5.4 ± 1.6
a
SVRI, dynes/sec/cm
5/m
2 1,588 ± 513 2,024 ± 616
a 1,435 ± 484 1,680 ± 535
a
CFI, cardiac function index; CI, cardiac index; DAP, diastolic arterial pressure; GEDVI, global end-diastolic volume index; HR, heart rate; LVEF, left ventricular
function; MAP, mean arterial pressure; NE, norepinephrine; SVI, stroke volume index; SVRI, index of systemic vascular resistance.
aP < 0.05 vs. before norepinephrine.
Figure 5 Relative changes in the individual values of the stroke
volume index (SVI) and of the end-diastolic volume index
(GEDVI) before and after norepinephrine introduction (or
increase in its doses) in the subgroup of 71 patients with a left
ventricular ejection fraction (LVEF) >45%. The arrows indicate
the directions of these changes.
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results to sepsis patients with no or less-severe hypoten-
sion – as those studied by Rivers et al. [13] – that are gen-
erally fully volume resuscitated before receiving
norepinephrine. The fact that norepinephrine is able to
improve hemodynamics, mainly through a preload effect
during the early life-threatening phase, cannot imply that
norepinephrine should be used instead of fluid at later
periods. It is rather generally advised to make efforts to
reduce the dose of the vasopressor as soon as possible [1],
with the possibility of infusing fluid in case of unmasked
cardiac preload reserve.
The aim of resuscitation is not only to correct hypo-
tension but also to improve tissue oxygenation. During
experimental endotoxic shock, Sennoun et al. [21]
showed that early administration of norepinephrine in
addition to fluid infusion resulted in a lower lactate
level than in the case of fluid infusion alone. In our
study, because we did not examine the changes in blood
lactate levels, we cannot ensure that tissue oxygenation
also improved after the MAP has been corrected.
Conclusions
During septic shock with life-threatening hypotension,
early administration of norepinephrine aimed at achiev-
ing a sufficient perfusion pressure is also able to
increase cardiac output through increases in cardiac pre-
load and contractility. Such a beneficial effect remained
significant in patients with poor cardiac contractility,
except when MAP values ≥75 mm Hg were achieved.
Key messages
￿ Early administration of norepinephrine aimed at
rapidly achieving a sufficient perfusion pressure in
severely hypotensive septic-shock patients is able to
increase cardiac output.
￿ The increase in cardiac output with norepinephr-
ine seems to be related to increases in both cardiac
preload and cardiac contractility.
￿ These positive effects can be observed even in
patients with poor cardiac contractility, except when
values of MAP ≥75 mm Hg are achieved.
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ventricular ejection fraction (LVEF) ≤45%. The arrows indicate
the directions of these changes.
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